sodium oxybate NDC 72865-349

NDC codes

FDA NDC Directory

Product NDC (as listed)72865-349Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72865-0349Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72865-349-18	72865034918	1 BOTTLE in 1 CARTON (72865-349-18) / 180 mL in 1 BOTTLEMarketed from Jan 1, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): sodium oxybate
Generic name (nonproprietary): sodium oxybate
Active ingredients: Sodium oxybate — .5 g/mL
Dosage form: Solution
Route: Oral
Labeler: XLCare Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210523
Marketing start: Jan 1, 2026
Listing expires: Dec 31, 2027
DEA schedule: CIII
Other FDA classes: Central Nervous System Depression (Physiologic effect)Decreased Central Nervous System Organized Electrical Activity (Physiologic effect)
Identifiers: Product ID 72865-349_978891be-92e4-4aa0-9e01-6733b1148bc3SPL ID 978891be-92e4-4aa0-9e01-6733b1148bc3SPL set ID c0fb2620-7247-464d-a37a-8b516ce7d563RxCUI 349482UNII 7G33012534
Pharmacologic class: Central Nervous System Depressant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472865034918 followed by a unit qualifier and the quantity

Package 72865-0349-18. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 6, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Sodium oxybate oral solution is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy. Pediatric use information is approved for Jazz Pharmaceuticals Inc.’s XYREM (sodium oxybate) Oral Solution. However, due to Jazz Pharmaceuticals Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Sodium oxybate oral solutio n is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy (1).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210523

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210523
Product	Strength	Form · route	Labeler	Product NDC
sodium oxybate	Sodium oxybate .5 g/mL	SolutionOral	Camber Pharmaceuticals, Inc.	31722-891